Screening for cervical cancer in the era of the HPV vaccine - The urgent need for both new screening guidelines and new biomarkers

Journal of the National Cancer Institute

Volumn 100, Issue 5, 2008, Pages 290-291

  Kiviat, Nancy B ^a,b   Hawes, Stephen E ^a   Feng, Qinghua ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; VIRUS DNA; WART VIRUS VACCINE; TUMOR MARKER;

CANCER RISK; CANCER SCREENING; COMPARATIVE STUDY; CYTOLOGY; DIAGNOSTIC VALUE; DNA DETERMINATION; EDITORIAL; HEALTH CARE NEED; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; VIRUS TYPING; AGE; ALPHAPAPILLOMAVIRUS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; METABOLISM; METHODOLOGY; NOTE; STANDARD; STATISTICAL MODEL; UNITED STATES; UTERINE CERVIX TUMOR; VIROLOGY;

AGE FACTORS; ALPHAPAPILLOMAVIRUS; COST-BENEFIT ANALYSIS; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; MODELS, ECONOMETRIC; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 40949127004     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn038     Document Type: Editorial

References (10)

1. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008;100(5): 308-320.
2. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290(6):781-789.
3. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28-41.
4. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25(29):5399-5408.
5. Franco EL. Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr. 2003;31:89-96.
6. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95(1):46-52.
7. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. Chapter 10: new dimensions in cervical cancer screening. Vaccine. 2006;24(suppl 3):S90-S97.
8. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(suppl 3):S78-S89.
9. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-1588.
10. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111(3):145-153.